RA
ORKA

Royce & Associates’s Oruka Therapeutics ORKA Stock Holding History

Royce & Associates’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,510
Closed -$163K – 1262
2018
Q1 		$163K Buy
1,510
+6
+0.4% +$1.61K ﹤0.01% 1094
2017
Q4 		$447K Buy
1,504
+417
+38% +$121K ﹤0.01% 1048
2017
Q3 		$258K Buy
1,087
+254
+30% +$90.3K ﹤0.01% 1061
2017
Q2 		$441K Buy
833
+689
+478% +$359K ﹤0.01% 1044
2017
Q1 		$78K Buy
+144
New +$80.4K ﹤0.01% 1102
2016
Q4 		– Sell
-582
Closed -$363K – 1112
2016
Q3 		$363K Sell
582
-125
-18% -$80.6K ﹤0.01% 1017
2016
Q2 		$443K Sell
707
-125
-15% -$92.5K ﹤0.01% 1000
2016
Q1 		$617K Buy
+832
New +$677K ﹤0.01% 966

Other funds holding ORKA

TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royce & Associates's ORKA Position: Q2 2018 in Review

Royce & Associates sold out of Oruka Therapeutics (ORKA) in Q2 2018, closing a stake of 1,510 shares — an estimated $163K sold.

Royce & Associates first reported a position in ORKA in Q1 2016 and held it in 8 quarters. The position peaked at $617K in Q1 2016. 15 funds tracked by Wall St. Rank hold ORKA as of Q2 2018.

  • Royce & Associates reported no remaining Oruka Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Royce & Associates sold 1,510 Oruka Therapeutics shares in Q2 2018, an estimated $163K.
  • Royce & Associates first reported a position in Oruka Therapeutics in Q1 2016 and held it in 8 quarters.
  • Royce & Associates's Oruka Therapeutics position peaked at $617K in Q1 2016.
  • 15 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.